Incidence, Clinical Features, and Contributing Factors of Capecitabine-Related Hand–Foot Syndrome in Cancer Patients: Insights from Sudan - Takeaways - MDSpire

Incidence, Clinical Features, and Contributing Factors of Capecitabine-Related Hand–Foot Syndrome in Cancer Patients: Insights from Sudan

  • By

  • Ola K. Obeid

  • Bashir A. Yousef

  • Yousif B. Hamadalneel

  • Mawahib A. Mustafa

  • Amani Abdelaziz Mahmoud

  • Elkhanssa Abdelhameed Ahmed Elhag

  • April 3, 2026

  • 0 min

Share

  • 1

    Over 50% of Sudanese cancer patients on capecitabine develop hand-foot syndrome, impacting their quality of life and treatment adherence.

  • 2

    Female patients and those undergoing multiple chemotherapy cycles are less likely to experience hand-foot syndrome.

  • 3

    Absence of concomitant diseases increases the likelihood of developing hand-foot syndrome in patients receiving capecitabine.

  • 4

    Early recognition and management of hand-foot syndrome can enhance patient quality of life and minimize treatment interruptions.

  • 5

    The study highlights the need for customized grading criteria for hand-foot syndrome to accurately assess severity in diverse populations.

Original Source(s)

Incidence, Clinical Features, and Contributing Factors of Capecitabine-Related Hand–Foot Syndrome in Cancer Patients: Insights from Sudan

  • by Ola K. Obeid, Bashir A. Yousef, Yousif B. Hamadalneel, Mawahib A. Mustafa, Amani Abdelaziz Mahmoud, Elkhanssa Abdelhameed Ahmed Elhag

  • April 3, 2026

Related Content

A top WHO official confronts Iran war fallout, and weighs bid for an even bigger role

Therapeutic cancer vaccines: Navigating clinical translation and multimodal synergy

Inequities in the Presentation of Disease and the Start of Treatment for De Novo Metastatic Breast Cancer